119 completed, 65 unknown, 16 recruiting, 13 not yet recruiting. 99 Phase 1, 58 Phase 3, 27 Phase 4, 15 Phase 2, 13 Not applicable.
Follow Daewoong Pharmaceutical Co. LTD.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of DWP450 in Japanese Subjects With Glabellar Lines DWP450 20 U, 0.9% Saline Solution 0.5 mL - Glabellar Lines | Phase 3 | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 120 | 2027-01-01 | 2026-08-26 |
| Feasibility of Combination Therapy With Low-dose Statin and Ezetimibe in Patients With Minimal Subclinical Atherosclerosis Crezet 2.5/10mg, Litorvazet 5/10mg, Baroezet 1/10mg - Atherosclerosis Cardiovascular Disease | Phase 4 | Not yet recruiting | Yonsei University | 300 | 2026-11-10 | 2026-10-16 |
| Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer DWP14012 40mg (Fexuprazan), Lansoprazole 30mg - Gastric Ulcer | Phase 3 | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 384 | 2026-10-15 | 2026-07-28 |
| Efficacy and Safety of DWP14012 for Long-Term Maintenance Therapy in Patients With Healed Erosive Esophagitis DWP14012 20mg, DWP14012 20 mg placebo, DWC202517 15 mg - Healed Erosive Esophagitis | Phase 3 | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 420 | 2026-09-01 | 2026-08-13 |
| To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus DWP16001, DWC202518, Placebo of DWP16001 - T2DM (Type 2 Diabetes Mellitus) | Phase 3 | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 510 | 2026-06-01 | 2026-06-02 |
| A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers DWRX5003, DWC202502, DWC202503 - Obesity & Overweight, Type 2 Diabetes | Phase 1 | Recruiting | Daewoong Pharmaceutical Co. LTD. | 72 | 2026-05-06 | 2026-07-16 |
| Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice Peptic Ulcer, NSAID-Induced Peptic Ulcer | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 7000 | 2026-04-30 | 2026-04-30 | |
| Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study Dyslipidemia | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 12000 | 2026-04-30 | 2026-04-07 | |
| Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer DWZ2501 (Olaparib 150mg), DWC202510 (Olaparib 150mg) - Cancer, Ovarian Cancer | Phase 1 | Recruiting | Daewoong Pharmaceutical Co. LTD. | 40 | 2026-04-22 | 2026-05-08 |
| Noseguard for Prevention of Respiratory Infections in Real-World Use Noseguard and Noseguard Night - Respiratory Infection Virus, COVID-19 | Not applicable | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 2000 | 2026-04-20 | 2026-04-08 |
| Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer Fexuprazan 20mg, Lansoprazole 15 mg placebo, Lansoprazole 15 mg - NSAID (Non-Steroidal Anti-Inflammatory Drug) | Phase 4 | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 360 | 2026-04-01 | 2026-04-16 |
| Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition. DWJ1622, DWC202313, DWC202314 - Healthy Volunteers | Phase 1 | Recruiting | Daewoong Pharmaceutical Co. LTD. | 36 | 2025-12-01 | 2025-12-05 |
| PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers DWJ1445, DWC202506 - Healthy Subjects | Phase 1 | Completed | Daewoong Pharmaceutical Co. LTD. | 70 | 2025-11-14 | 2025-12-03 |
| Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults DWP16001, DWC202511, DWC202512 - Healthy | Phase 1 | Completed | Daewoong Pharmaceutical Co. LTD. | 18 | 2025-11-09 | 2026-02-11 |
| Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions DWJ1622, DWC202313, DWC202314 - Healthy Volunteers | Phase 1 | Recruiting | Daewoong Pharmaceutical Co. LTD. | 40 | 2025-11-05 | 2025-12-17 |
| CART BP Pro-Guided Blood Pressure Management for Uncontrolled Hypertension CART BP Pro, Usual Care - Hypertension | Not applicable | Recruiting | Korea University Anam Hospital | 400 | 2025-10-22 | 2026-04-30 |
| Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis Psoriasis | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 425 | 2025-09-30 | 2025-09-24 | |
| Observational Study to Evaluate the Efficacy of OLMETEC Tab on Nocturnal Blood Pressure Control in Patients With Stage Ⅰ Hypertension Stage 1 Hypertension | Recruiting | Daewoong Pharmaceutical Co. LTD. | 12000 | 2025-09-17 | 2026-04-07 | |
| PK and Safety Comparison of DWJ1511 and DWC202501 in Healthy Volunteers DWJ1511, DWC202501 - Healthy Subjects | Phase 1 | Recruiting | Daewoong Pharmaceutical Co. LTD. | 60 | 2025-09-01 | 2025-08-28 |
| Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines DWP712 inj., Botox® 100 Units - Glabellar Lines | Phase 3 | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 324 | 2025-07-15 | 2025-06-10 |
Showing 20 of 234. Sign in to see all of them.
Diabetes Mellitus, Type 2 (24) · Hypertension (15) · Dyslipidemias (12) · COVID-19 (6) · Diabetes Mellitus (4) · Gastritis (4) · Gastroesophageal Reflux (4) · Idiopathic Pulmonary Fibrosis (4) · Coronary Artery Disease (3) · Hepatitis B, Chronic (3) · Hyperlipidemias (3) · Obesity (3) · Peptic Ulcer (3) · Acute Coronary Syndrome (2) · Dry Eye Syndromes (2)
Enavogliflozin (28) · fexuprazan (25) · Rosuvastatin Calcium (11) · Botulinum Toxins, Type A (9) · Amlodipine (7) · Ursodeoxycholic Acid (7) · olmesartan (7) · Lansoprazole (6) · Olmesartan Medoxomil (5) · Saline Solution (5) · Esomeprazole (4) · Tablets (4) · DWP450 (3) · Ezetimibe (3) · Leuprolide (3)
South Korea (191) · China (4) · Indonesia (4) · United States (3) · Canada (2) · Australia (1)
Kyung-Sang Yu (3) · Hyo-Soo Kim, MD, PhD (2) · Jae-Gook Shin, Professor (2) · Kyungsoo Park, M.D., Ph.D. (2) · Ari Fahrial Syam, MD, PhD (1) · Beom Joon Kim, MD, Ph.D (1) · Beom Joon Kim, MD, PhD (1) · BuKyung Kim (1) · Bum Soon Choi, PhD (1) · Cheol-Young Park, MD (1) · Chong-hyun Won, MD, PhD (1) · Chun-Soo Lim, PhD (1)
PMID 36729473, PMID 38456558, PMID 39054871, PMID 24300020, PMID 24945238, PMID 25531146, PMID 26098847, PMID 26185033, PMID 26370136, PMID 26940115, PMID 26997458, PMID 27001664, PMID 27046149, PMID 30396252, PMID 31296866, PMID 32321551, PMID 32584935, PMID 32886935, PMID 33062629, PMID 33491668, PMID 33782940, PMID 34010616, PMID 34164803, PMID 35365239, PMID 36342475, PMID 36515544, PMID 36756676, PMID 36789577, PMID 37042284, PMID 37043192, PMID 37181388, PMID 37593838, PMID 37612109, PMID 37742741, PMID 37814541, PMID 37821166, PMID 38251791, PMID 38618974, PMID 38639876, PMID 38700290, PMID 39504016, PMID 39602157, PMID 40567214, PMID 40623657, PMID 40773465, PMID 41397686, PMID 41453443, PMID 41560483, PMID 41921522, PMID 42015653